2015 Annual Meeting On Demand: Monday Sessions

You can earn up to 8.5 AMA PRA Category 1 Credit(s). This activity has also been designated by the ABAI for 6.5 MOC Part II Self-Assessment credits.

This collection covers general sessions from Monday's program. This includes plenaries, symposia, and, for the first time, several workshops have been included. The sessions listed below are included in this package.

  • Food Allergy: Component Testing, CoFAR Studies, Practical Considerations
  • Updates in Severe Asthma
  • Update on Anaphylaxis 
  • W29 Immunotherapy SCIT/SLIT
  • W33 Anaphylaxis


Release Date: 12/15/2015
Expiration Date: 12/14/2018


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 8.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


Learning Objectives

• Identify and advise families with children who are at high risk of developing food allergy
• Discuss treatment options for patients who already have developed food allergy
• Monitor the burden of food allergy on families
• Recognize how basic science research has identified distinct pathophysiological endotypes in severe asthma 

• Utilize appropriate biomarkers to categorize the endotype of a severe asthma patient in the allergy/immunology clinic 
• Design a management plan that is individualized to a severe asthma patient's particular phenotype and endotype
• Diagnose mast cell activating disorders and distinguish them from idiopathic anaphylaxis, and discern when to do a bone marrow in these conditions

• Facilitate interaction with emergency department physicians to increase the referral for an allergy evaluation after a patient is discharged from the emergency department after an anaphylactic event 
• Skin test to discern the causative agent in anaphylaxis occurring during surgery
• Explain the differences between standardized and nonstandardized extracts
• Compose a therapeutic mix for immunotherapy through review of the literature
• Write prescriptions for immunotherapy which contain safe and effective doses of each component according to current guidelines and best clinical practice for the benefit of patient care
• Use current guidelines to improve the safety and effectiveness of immunotherapy in the office
• Explore the literature regarding SLIT
• Explore adherence to IT
• Administer epinephrine at the appropriate time to patients with various manifestations of anaphylaxis; and recognize that anaphylaxis may begin with mild symptoms and rapidly progress to cardiovascular and/or respiratory collapse


Additional information

Maeve E. O'Connor, MD, FACAAI -- Consultant/Advisor: Novartis; Speaker: Aerocrine, Baxter, Dyax, Greer, Meda, Merck, Mylan, Teva, Thermo Fisher Scientific

Matthew Greenhawt, MD, MBA, MSc, FACAAI -- Consultant/Advisor: National Peanut Board; Supported/Contracted Research: National Center for Translational Sciences 

Ruchi Gupta, MD, MPH -- Speaker: Mylan Specialty; Supported/Contracted Research: Food Allergy Research & Education, Mylan 

David M. Fleischer, MD, FACAAI -- No financial relationships to disclose

Stephen P. Peters, MD, PhD -- Consultant/Advisor: AstraZeneca, Boehringer Ingelheim, CSL Behring, Gilead, Merck, Novartis, Pfizer, Teva, PPD Development, Quintiles, Theron

Bradley E. Chipps, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Boehringer Ingelheim, Genentech, Merck, Novartis; Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Merck, Novartis; Supported/Contracted Research: Stallergenes

Phillip L. Lieberman, MD, FACAAI -- Consultant/Advisor: Genentech, Mylan, Teva, Valeant; Speaker: Meda

Cem Akin, MD, PhD -- Consultant/Advisor: Blueprint Medicines, Novartis, Patara Pharma; Supported/Contracted Research: Dyax

Lene Heise Garvey, MD -- Consultant/Advisor: Merck; Speaker: Thermo Fisher Scientific

John J. Oppenheimer, MD, FACAAI -- Consultant/Advisor: GlaxoSmithKline, Meda, Mylan; Supported/Contracted Research: AstraZeneca, MedImmune, Novartis

Paul A. Greenberger, MD, FACAAI -- Consultant/Advisor: Allergy Therapeutics, Merck

The following have no financial relationships to disclose:

Gerald B. Lee, MD

Elliot Israel, MD

Ronna L. Campbell, MD, PhD

Bryan L. Martin, DO, FACAAI

Course summary
Available credit: 
  • 8.50 AMA PRA Category 1 Credit™
  • 8.50 Attendance
  • 6.50 MOC
Course opens: 
Course expires: 

Available Credit

  • 8.50 AMA PRA Category 1 Credit™
  • 8.50 Attendance
  • 6.50 MOC
Please login or create an account to take this course.